Q32 Bio Inc.
QTTB
$1.61
-$0.075-4.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -14.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -14.66M |
| Cost of Revenue | 10.55M | 14.35M | 13.41M | 9.84M | 8.34M |
| Gross Profit | -10.55M | -14.35M | -13.41M | -9.84M | -23.00M |
| SG&A Expenses | 3.98M | 4.47M | 4.51M | 5.00M | 2.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.53M | 18.81M | 17.92M | 14.84M | 11.15M |
| Operating Income | -14.53M | -18.81M | -17.92M | -14.84M | -25.81M |
| Income Before Tax | -15.79M | -17.60M | -15.53M | 1.21M | -26.81M |
| Income Tax Expenses | -1.60M | -- | 1.45M | 176.00K | 253.00K |
| Earnings from Continuing Operations | -14.19M | -17.60M | -16.98M | 1.03M | -27.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.19M | -17.60M | -16.98M | 1.03M | -27.07M |
| EBIT | -14.53M | -18.81M | -17.92M | -14.84M | -25.81M |
| EBITDA | -14.41M | -18.69M | -17.80M | -14.72M | -25.69M |
| EPS Basic | -1.16 | -1.46 | -1.42 | 1.03 | -76.38 |
| Normalized Basic EPS | -1.63 | -0.87 | -0.81 | 0.76 | -36.37 |
| EPS Diluted | -1.16 | -1.46 | -1.42 | -6.33 | -76.38 |
| Normalized Diluted EPS | -1.63 | -0.87 | -0.81 | 0.32 | -36.37 |
| Average Basic Shares Outstanding | 12.18M | 12.08M | 11.96M | 995.30K | 354.40K |
| Average Diluted Shares Outstanding | 12.18M | 12.08M | 11.96M | 2.33M | 354.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |